Dubai Telegraph - Big Pharma push back on first Medicare drug price cuts

Their statements came after US President Joe Biden and Vice President Kamala Harris announced a deal to lower costs of the first 10 drugs picked for Medicare price talks.

The agreement with drugmakers -- who said they came on board with negotiations as they had no choice -- is set to save seniors in the United States $1.5 billion in out-of-pocket costs.

It is the result of months of negotiations and is anticipated to save Medicare $6 billion in the first year alone, said Biden, referring to the federal health insurance for seniors.

While the announcement is a likely boon for Democratic presidential candidate Harris as she works on her economic messaging ahead of November's election, pharmaceutical companies have long resisted the cuts.

The US government is initially limited to picking 10 drugs for price talks and can expand the program in subsequent years.

- 'Not objective' -

The agreements come on the back of the Inflation Reduction Act (IRA), a major package of energy transition policy and social reforms.

This allowed Medicare to start negotiating drug costs for the first time in its nearly 60-year existence.

Novartis, whose heart failure treatment Entresto is among the 10 selected medicines, pushed back against the price-setting process as "not objective or transparent."

"Novartis believes the price-setting provisions in the IRA are unconstitutional and will have long-lasting and devastating consequences," the company added in a statement.

It said it agreed to a "maximum fair price" only to "avoid other untenable options including catastrophic fines or the removal of all our products from both Medicare and Medicaid."

For the 10 selected drugs, discounts from 2023 prices range from 38 percent to 79 percent. The new costs will take effect in 2026.

Besides Entresto, the drugs include Farxiga by AstraZeneca used against diabetes, as well as anticoagulant Eliquis -- used by millions of Medicare beneficiaries.

AstraZeneca said in a separate statement that it accepted the price, as "walking away is not an option."

If a manufacturer refused to accept the price, access for Medicare and Medicaid patients could be compromised, it said.

- Patient costs? -

Companies also warned that patients could still face higher costs and argued that the deal undervalued their products.

Bristol Myers Squibb (BMS), which is behind Eliquis, cautioned that "insurance plans and their pharmacy benefit managers are ultimately responsible for what patients will pay."

"The IRA does not protect patients from potential increases to their cost sharing or restrictions in access" to Eliquis once the maximum fair price goes into effect in 2026, the company added.

CFRA analyst Sel Hardy, however, noted that BMS management seemed confident it could navigate the impact of the IRA on Eliquis.

A Johnson & Johnson spokesperson called the law arbitrary and lacking in scientific approach.

This "undervalues the benefit our medicines deliver to millions of patients," J&J said.

- 'Historic milestone' -

US residents face the highest prescription drug prices globally, leaving many people to pay partially out of their own pockets despite already exorbitant insurance premiums.

The new deal was reached after Democrats pushed for the government to be able to negotiate prices directly with drug manufacturers for federal health programs.

The White House said the agreement for lower prices is a "historic milestone."

"The vice president and I are not backing down," Biden said in a Thursday statement.

His comments came ahead of a first joint public event with Harris since she replaced him as the Democratic candidate in the upcoming election.

"We will continue the fight to make sure all Americans can pay less for prescription drugs and to give more breathing room for American families," he said.

Rising costs of living are a key issue for the 2024 election.

Last October, drugmakers behind the selected medicines for serious illnesses grudgingly agreed to negotiate on cutting prices.

A.Padmanabhan--DT